Similar articles

• Differential operation of MLH1/MSH2 and FANCD2 crosstalk in chemotolerant bladder carcinoma: a clinical and therapeutic intervening study.

  Basu M, Mukhopadhyay D, Chakraborty B, Ghosh S, Pal DK, Ghosh A, Panda CK. Basu M, et al. Mol Cell Biochem. 2023 Jul;478(7):1599-1610. doi: 10.1007/s11010-022-04616-9. Epub 2022 Nov 24. Mol Cell Biochem. 2023. Retraction in: Mol Cell Biochem. 2024 Jul;479(7):1865. doi: 10.1007/s11010-024-05021-0. PMID: 36434146 Retracted.
• Hypomethylation of mismatch repair genes MLH1 and MSH2 is associated with chemotolerance of breast carcinoma: Clinical significance.

  Dasgupta H, Islam S, Alam N, Roy A, Roychoudhury S, Panda CK. Dasgupta H, et al. J Surg Oncol. 2019 Jan;119(1):88-100. doi: 10.1002/jso.25304. Epub 2018 Nov 27. J Surg Oncol. 2019. PMID: 30481381
• A Rare MSH2 Variant as a Candidate Marker for Lynch Syndrome II Screening in Tunisia: A Case of Diffuse Gastric Carcinoma.

  Kabbage M, Ben Aissa-Haj J, Othman H, Jaballah-Gabteni A, Laarayedh S, Elouej S, Medhioub M, Kettiti HT, Khsiba A, Mahmoudi M, BelFekih H, Maaloul A, Touinsi H, Hamzaoui L, Chelbi E, Abdelhak S, Boubaker MS, Azzouz MM. Kabbage M, et al. Genes (Basel). 2022 Jul 28;13(8):1355. doi: 10.3390/genes13081355. Genes (Basel). 2022. PMID: 36011265 Free PMC article.
• Expression of MLH1 and MSH2 in urothelial carcinoma of the renal pelvis.

  Ehsani L, Osunkoya AO. Ehsani L, et al. Tumour Biol. 2014 Sep;35(9):8743-7. doi: 10.1007/s13277-014-2141-4. Epub 2014 May 30. Tumour Biol. 2014. PMID: 24874052
• Deficiency of hMLH1 and hMSH2 expression is a poor prognostic factor in esophageal squamous cell carcinoma.

  Uehara H, Miyamoto M, Kato K, Cho Y, Kurokawa T, Murakami S, Fukunaga A, Ebihara Y, Kaneko H, Hashimoto H, Murakami Y, Shichinohe T, Kawarada Y, Itoh T, Okushiba S, Kondo S, Katoh H. Uehara H, et al. J Surg Oncol. 2005 Nov 1;92(2):109-15. doi: 10.1002/jso.20332. J Surg Oncol. 2005. PMID: 16231369